{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:18Z","timestamp":1792787298716,"version":"4.5.0"},"reference-count":56,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chonnam National University Hwasun Hospital Institute for Biomedical Science","award":["HCRI25011"],"award-info":[{"award-number":["HCRI25011"]}],"id":[{"id":"https:\/\/ror.org\/054gh2b75","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF), funded by the Korean government","award":["NRF-2020M3A9G3080281"],"award-info":[{"award-number":["NRF-2020M3A9G3080281"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF), funded by the Korean government","award":["No. RS-2025-02216943"],"award-info":[{"award-number":["No. RS-2025-02216943"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF), funded by the Korean government","award":["RS-2023-00218543"],"award-info":[{"award-number":["RS-2023-00218543"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,15]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PTPN22, a protein tyrosine phosphatase (PTP) family member, has recently emerged as an intracellular regulator in adaptive immune cells. However, its function in natural killer (NK) cells remains unclear despite its high expression in innate immune cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed single-cell RNA-sequencing (scRNA-seq) datasets and The Cancer Genome Atlas (TCGA) to evaluate PTPN22 expression in NK cells and its association with clinical outcomes. We established a CRISPR-mediated PTPN22 knockout platform for NK cell gene editing and evaluated PTPN22 function using both genetic deletion and pharmacological inhibition across multiple NK cell platforms. Cytotoxicity and cytokine production were assessed against hematologic and solid tumor targets, including CD19\n                      <jats:sup>+<\/jats:sup>\n                      and mesothelin-positive (MSLN\n                      <jats:sup>+<\/jats:sup>\n                      ) cancer cells. PTPN22 knockout (PTPN22\n                      <jats:sup>KO<\/jats:sup>\n                      ) anti-CD19\/CAR-NK92 cells were tested in Nalm6 xenograft models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Published scRNA-seq datasets showed that PTPN22 was highly expressed in tumor-infiltrating NK cells. PTPN22\n                      <jats:sup>high<\/jats:sup>\n                      NK cells exhibited stress and dysfunction signatures within inflammatory and immunosuppressive tumor microenvironments (TME), with elevated PTPN22 expression in TCGA associated with poorer patient survival. Genetic deletion of PTPN22 or pharmacological inhibition enhanced NK-cell cytotoxicity and pro-inflammatory cytokine release and improved the antitumor activity of chimeric antigen receptor (CAR)-NK cells against CD19\n                      <jats:sup>+<\/jats:sup>\n                      and MSLN\n                      <jats:sup>+<\/jats:sup>\n                      targets. PTPN22\n                      <jats:sup>KO<\/jats:sup>\n                      preserved CAR-NK cell function under cytokine-based TME-like conditions and improved the functional persistence of primary anti-CD19 CAR-NK cells during prolonged tumor exposure. PTPN22\n                      <jats:sup>KO<\/jats:sup>\n                      NK and CAR-NK cells showed increased or preserved signal transducer and activator of transcription 3 (STAT3) phosphorylation and reduced FAS expression under inflammatory conditions. Notably, PTPN22\n                      <jats:sup>KO<\/jats:sup>\n                      anti-CD19\/CAR-NK92 cells demonstrated superior anti-leukemic activity and significantly prolonged survival compared with non-knockout controls in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings identify PTPN22 as a novel intracellular checkpoint that limits NK and CAR-NK cell function. Targeted deletion of PTPN22 represents a promising strategy to enhance the therapeutic efficacy and persistence of both unmodified and CAR-engineered NK cells for cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-016896","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:41:32Z","timestamp":1790862092000},"page":"e016896","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy"],"prefix":"10.1136","volume":"14","author":[{"given":"Tung Nguyen Thanh","family":"Uong","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea"},{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-926X","authenticated-orcid":false,"given":"Meesun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea"},{"name":"Immunotherapy Innovation Center, Chonnam National University Medical School, Gwangju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhat Phuoc Nguong Minh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Chonnam National University Graduate School, Hwasun-gun, Korea"},{"name":"Department of Biopharmaceutical Convergence, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Kwon","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Uk","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hyub","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duck","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea"},{"name":"Department of Biopharmaceutical Convergence, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106151668000_14.10.e016896.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0"},{"key":"2026100106151668000_14.10.e016896.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016200"},{"key":"2026100106151668000_14.10.e016896.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x"},{"key":"2026100106151668000_14.10.e016896.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026100106151668000_14.10.e016896.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"2026100106151668000_14.10.e016896.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8"},{"key":"2026100106151668000_14.10.e016896.7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"2026100106151668000_14.10.e016896.8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat Cancer"},{"key":"2026100106151668000_14.10.e016896.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026100106151668000_14.10.e016896.10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"2026100106151668000_14.10.e016896.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026100106151668000_14.10.e016896.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322"},{"key":"2026100106151668000_14.10.e016896.13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"2026100106151668000_14.10.e016896.14","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4(1)","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"2026100106151668000_14.10.e016896.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023529"},{"key":"2026100106151668000_14.10.e016896.16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014592"},{"key":"2026100106151668000_14.10.e016896.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"},{"key":"2026100106151668000_14.10.e016896.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-Mediated Tumor Immunity by TGF-\u03b2","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front Immunol"},{"key":"2026100106151668000_14.10.e016896.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-025-01140-z","article-title":"Mechanistic insights into IL-6-mediated NK cell dysfunction in NSCLC via the IRE1\u03b1-XBP1s-STAT3-UBE2S axis","volume":"9","author":"Wang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026100106151668000_14.10.e016896.20","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"key":"2026100106151668000_14.10.e016896.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK Cell Exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front Immunol"},{"key":"2026100106151668000_14.10.e016896.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00618-w"},{"key":"2026100106151668000_14.10.e016896.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0934"},{"key":"2026100106151668000_14.10.e016896.24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.000505"},{"key":"2026100106151668000_14.10.e016896.25","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6108","article-title":"SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells","volume":"5","author":"Viant","year":"2014","journal-title":"Nat Commun"},{"key":"2026100106151668000_14.10.e016896.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900088"},{"key":"2026100106151668000_14.10.e016896.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09431-3","article-title":"Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells","volume":"10","author":"Niogret","year":"2019","journal-title":"Nat Commun"},{"key":"2026100106151668000_14.10.e016896.28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001439","article-title":"Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy","volume":"8","author":"Cubas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026100106151668000_14.10.e016896.29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/17460441.2022.2084607","article-title":"PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy","volume":"17","author":"Jassim","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"2026100106151668000_14.10.e016896.30","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146950","article-title":"Systemic inhibition of PTPN22 augments anticancer immunity","volume":"131","author":"Ho","year":"2021","journal-title":"J Clin Invest"},{"key":"2026100106151668000_14.10.e016896.31","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12919"},{"key":"2026100106151668000_14.10.e016896.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007614","article-title":"Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion","volume":"11","author":"Teagle","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026100106151668000_14.10.e016896.33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy","volume":"27","author":"Wu","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"2026100106151668000_14.10.e016896.34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","article-title":"CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells","volume":"643","author":"Rafei","year":"2025","journal-title":"Nature"},{"key":"2026100106151668000_14.10.e016896.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02103-z"},{"key":"2026100106151668000_14.10.e016896.36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ccell.2025.05.011","article-title":"Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling","volume":"43","author":"Nikolic","year":"2025","journal-title":"Cancer Cell"},{"key":"2026100106151668000_14.10.e016896.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.05.008"},{"key":"2026100106151668000_14.10.e016896.38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3343\/alm.2025.0168","article-title":"Optimization of Natural Killer Cell Expansion with K562-mbIL-18\/-21 Feeder Cells and Assurance of Feeder Cell-free Products","volume":"46","author":"Jo","year":"2026","journal-title":"Ann Lab Med"},{"key":"2026100106151668000_14.10.e016896.39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood.2024025673","article-title":"Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T\/-NK cells and reduces trogocytosis","volume":"145","author":"Koh","year":"2025","journal-title":"Blood"},{"key":"2026100106151668000_14.10.e016896.40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac959"},{"key":"2026100106151668000_14.10.e016896.41","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-023-06816-9"},{"key":"2026100106151668000_14.10.e016896.42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/2326-6066.CIR-25-1229","article-title":"Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors","volume":"14","author":"Lozada","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"2026100106151668000_14.10.e016896.43","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.916"},{"key":"2026100106151668000_14.10.e016896.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2010.01512.x"},{"key":"2026100106151668000_14.10.e016896.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0137-0"},{"key":"2026100106151668000_14.10.e016896.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.09.018"},{"key":"2026100106151668000_14.10.e016896.47","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026100106151668000_14.10.e016896.48","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2519903123","article-title":"An autoimmunity-associated allele of PTPN22 enhances innate antiviral immunity to protect against acute coronavirus infection","volume":"123","author":"Bevis","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100106151668000_14.10.e016896.49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp8166","article-title":"IFN-\u03b3\u2013resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models","volume":"17","author":"Bailey","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026100106151668000_14.10.e016896.50","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41551-024-01282-8","article-title":"Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells","volume":"8","author":"Menegatti","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"2026100106151668000_14.10.e016896.51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947568","article-title":"The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance","volume":"13","author":"Witalisz-Siepracka","year":"2022","journal-title":"Front Immunol"},{"key":"2026100106151668000_14.10.e016896.52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/JLB.2A1118-421R","article-title":"STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients","volume":"106","author":"Zheng","year":"2019","journal-title":"J Leukoc Biol"},{"key":"2026100106151668000_14.10.e016896.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564450"},{"key":"2026100106151668000_14.10.e016896.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.011"},{"key":"2026100106151668000_14.10.e016896.55","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026100106151668000_14.10.e016896.56","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00583-7","article-title":"The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances","volume":"13","author":"Yao","year":"2024","journal-title":"Exp Hematol Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-016896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:41:36Z","timestamp":1790862096000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-016896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-016896"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-016896","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}